Established in 1994 in the Kingdom of Saudi Arabia, Tabuk Pharma is recognized as a leading company in the development and manufacturing of high-quality medicines. Over more than three decades, the company has expanded its presence to 17 countries across the Middle East and North Africa, supported by advanced expertise and modern manufacturing capabilities. In alignment with Saudi Vision 2030, Tabuk Pharma is committed to localizing the pharmaceutical industry and empowering national talents, contributing to the sustainability of the healthcare sector and the advancement of the healthcare ecosystem across the region.
H1 2026 Highlights
- Accelerated public sector sales through tender opportunities (NUPCO extension)
- Entered new therapy areas with the launch of Freshvue (Ophthalmology) and Racad (Pediatric GIT)
- Strong growth from recently launched products including Roneza (Cardiovascular), Divido combo (Pain) and Omiz Plus (GIT)
- 15+ licensing agreements executed in H1 2026, expanding the pipeline in Oncology and Ophthalmology
- New tolling agreements with multinational companies, leveraging Tabuk’s manufacturing capabilities
- Maintained leadership in key therapeutic areas while expanding into new ones
30+ years of experience
4 advanced manufacturing facilities
250+ registered products
17 countries across MENA
Strategic partnerships with global industry leaders
